TROG Cancer Research
Members Login   CQMS Login

Upcoming gastrointestinal trials

 

TD 16.05 (ACT5) - this study aims to investigate the role of radiotherapy dose escalation in locally advanced anal cancer and determine if this can reduce local recurrence.

Primary sponsor: National Cancer Research Institute (NCRI)
Collaborating group: TROG

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.